| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 7. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | beclometasone dipropionate / formoterol fumarate dihydrate (Luforbec®) |
| Formulation | 100 / 6 micrograms inhalation solution |
| Reference number | 4925 |
| Indication | Regular treatment of asthma where use of an inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination is appropriate: patients not adequately controlled with ICS and as needed short-acting beta2-agonist, or patients already adequately controlled on both ICS and LABA. COPD: Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. |
| Company | Lupin Healthcare (UK) Ltd |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 24/06/2021 |